Itau Unibanco Holding S.A. boosted its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 136.4% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,363 shares of the biopharmaceutical company’s stock after buying an additional 5,403 shares during the quarter. Itau Unibanco Holding S.A.’s holdings in Bristol-Myers Squibb were worth $573,000 at the end of the most recent quarter.
Other hedge funds have also recently made changes to their positions in the company. Delphi Private Advisors LLC bought a new position in Bristol-Myers Squibb during the fourth quarter valued at about $108,000. Massey Quick Simon & CO. LLC boosted its stake in Bristol-Myers Squibb by 523.5% during the third quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 1,492 shares in the last quarter. Horan Capital Advisors LLC. bought a new position in Bristol-Myers Squibb during the third quarter valued at about $122,000. NuWave Investment Management LLC acquired a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at $119,000. Finally, Atlantic Trust LLC acquired a new position in shares of Bristol-Myers Squibb in the 2nd quarter valued at $111,000. 71.49% of the stock is owned by institutional investors and hedge funds.
A number of equities analysts recently weighed in on BMY shares. Citigroup set a $72.00 price target on Bristol-Myers Squibb and gave the company a “buy” rating in a research report on Tuesday, December 5th. BMO Capital Markets set a $49.00 price target on Bristol-Myers Squibb and gave the company a “sell” rating in a research report on Monday, December 11th. Vetr lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $59.70 price target for the company. in a research report on Friday, December 22nd. Zacks Investment Research lowered Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Finally, Credit Suisse Group set a $62.00 price target on Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Monday, January 22nd. Three equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have given a buy rating to the company. Bristol-Myers Squibb presently has an average rating of “Hold” and a consensus price target of $66.79.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Monday, February 5th. The biopharmaceutical company reported $0.68 EPS for the quarter, topping the Zacks’ consensus estimate of $0.67 by $0.01. Bristol-Myers Squibb had a return on equity of 35.43% and a net margin of 4.85%. The firm had revenue of $5.45 billion during the quarter, compared to analyst estimates of $5.35 billion. During the same period last year, the company posted $0.63 EPS. The business’s quarterly revenue was up 3.9% compared to the same quarter last year. equities analysts predict that Bristol-Myers Squibb Co will post 3.22 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 1st. Shareholders of record on Friday, April 6th will be given a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, April 5th. This represents a $1.60 dividend on an annualized basis and a yield of 2.50%. Bristol-Myers Squibb’s payout ratio is presently 271.19%.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.